221136-76-1Relevant articles and documents
Discovery and clinical evaluation of 1-{N-[2-(amidinoaminooxy)ethyl]amino} carbonylmethyl-6-methyl-3-[2,2-difluoro-2-phenylethylamino]pyrazinone (RWJ-671818), a thrombin inhibitor with an oxyguanidine P1 motif
Lu, Tianbao,Markotan, Thomas,Ballentine, Shelley K.,Giardino, Edward C.,Spurlino, John,Brown, Kathryn,Maryanoff, Bruce E.,Tomczuk, Bruce E.,Damiano, Bruce P.,Shukla, Umesh,End, David,Andrade-Gordon, Patricia,Bone, Roger F.,Player, Mark R.
experimental part, p. 1843 - 1856 (2010/08/06)
We have identified RWJ -671818 (8) as a, novel, low molecular weight, orally active inhibitor of human a-thrombin (Ki = 1.3 nM) that is potentially useful for the acute and chronic treatment of venous and, arterial thrombosis. In a rat deep ven
Cyclic oxyguanidine pyrazinones as protease inhibitors
-
, (2008/06/13)
Cyclic oxyguanidine pyrazinone compounds are described, including compounds of the Formula I: wherein R3, R4, R5, W, and A are as set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable
